Eric Weinlander1, Yash Somnay1, April D Harrison1, Cheng Wang2, Yi-Qiang Cheng3, Renata Jaskula-Sztul1, Xiao-Min Yu4, Herbert Chen5. 1. Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 2. Department of Biological Sciences, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin. 3. Department of Biological Sciences, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin; UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas. 4. Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: yux@surgery.wisc.edu. 5. Endocrine Surgery Research Laboratories, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: chen@surgery.wisc.edu.
Abstract
BACKGROUND: Anaplastic thyroid cancer (ATC) remains refractory to available surgical and medical interventions. Histone deacetylase (HDAC) inhibitors are an emerging targeted therapy with antiproliferative activity in a variety of thyroid cancer cell lines. Thailandepsin A (TDP-A) is a novel class I HDAC inhibitor whose efficacy remains largely unknown in ATC. Therefore, we aimed to characterize the effect of TDP-A on ATC. METHODS: Human-derived ATC cells were treated with TDP-A. IC50 was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) rapid colorimetric assay, and cell proliferation was measured by viable cell count. Molecular mechanisms of cell growth inhibition were investigated by Western blot analysis of canonical apoptosis markers, intrinsic and extrinsic apoptosis regulators, and cell cycle regulatory proteins. Cell cycle staging was determined with propidium iodide flow cytometry. RESULTS: TDP-A dose- and time-dependently reduced cell proliferation. Increased cleavage of the apoptosis markers Caspase-9, Caspase-3, and poly adenosine diphosphate ribose polymerase were observed with TDP-A treatment. Levels of the intrinsic apoptosis pathway proteins BAD, Bcl-XL, and BAX remained unchanged. Importantly, the extrinsic apoptosis activator cleaved Caspase-8 increased dose-dependently, and the antiapoptotic proteins Survivin and Bcl-2 decreased. Among the cell cycle regulatory proteins, levels of CDK inhibitors p21/WAF1 and p27/KIP increased. Flow cytometry showed that ATC cells were arrested in G2/M phase with diminished S phase after TDP-A treatment. CONCLUSIONS: TDP-A induces a notable dose- and time-dependent antiproliferative effect on ATC, which is mainly attributed to extrinsic apoptosis with concomitant cell cycle arrest. TDP-A therefore warrants further preclinical and clinical investigations.
BACKGROUND:Anaplastic thyroid cancer (ATC) remains refractory to available surgical and medical interventions. Histone deacetylase (HDAC) inhibitors are an emerging targeted therapy with antiproliferative activity in a variety of thyroid cancer cell lines. Thailandepsin A (TDP-A) is a novel class I HDAC inhibitor whose efficacy remains largely unknown in ATC. Therefore, we aimed to characterize the effect of TDP-A on ATC. METHODS:Human-derived ATC cells were treated with TDP-A. IC50 was determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) rapid colorimetric assay, and cell proliferation was measured by viable cell count. Molecular mechanisms of cell growth inhibition were investigated by Western blot analysis of canonical apoptosis markers, intrinsic and extrinsic apoptosis regulators, and cell cycle regulatory proteins. Cell cycle staging was determined with propidium iodide flow cytometry. RESULTS:TDP-A dose- and time-dependently reduced cell proliferation. Increased cleavage of the apoptosis markers Caspase-9, Caspase-3, and poly adenosine diphosphate ribose polymerase were observed with TDP-A treatment. Levels of the intrinsic apoptosis pathway proteins BAD, Bcl-XL, and BAX remained unchanged. Importantly, the extrinsic apoptosis activator cleaved Caspase-8 increased dose-dependently, and the antiapoptotic proteins Survivin and Bcl-2 decreased. Among the cell cycle regulatory proteins, levels of CDK inhibitors p21/WAF1 and p27/KIP increased. Flow cytometry showed that ATC cells were arrested in G2/M phase with diminished S phase after TDP-A treatment. CONCLUSIONS:TDP-A induces a notable dose- and time-dependent antiproliferative effect on ATC, which is mainly attributed to extrinsic apoptosis with concomitant cell cycle arrest. TDP-A therefore warrants further preclinical and clinical investigations.
Authors: Xiao-Min Yu; Renata Jaskula-Sztul; Kamal Ahmed; April D Harrison; Muthusamy Kunnimalaiyaan; Herbert Chen Journal: Mol Cancer Ther Date: 2013-04-17 Impact factor: 6.261
Authors: Alexander I Damanakis; Sabine Eckhardt; Annette Wunderlich; Silvia Roth; Thaddeus T Wissniowski; Detlef K Bartsch; Pietro Di Fazio Journal: J Cancer Res Clin Oncol Date: 2016-03-09 Impact factor: 4.553
Authors: S Jang; X-M Yu; S Odorico; M Clark; R Jaskula-Sztul; C M Schienebeck; K R Kupcho; A D Harrison; G N Winston-McPherson; W Tang; H Chen Journal: Cancer Gene Ther Date: 2015-08-07 Impact factor: 5.987
Authors: Samuel Jang; Haining Jin; Madhuchhanda Roy; Alice L Ma; Shaoqin Gong; Renata Jaskula-Sztul; Herbert Chen Journal: Cancer Med Date: 2017-08-04 Impact factor: 4.452
Authors: Samuel Jang; Andrew Janssen; Zviadi Aburjania; Matthew B Robers; April Harrison; Ajitha Dammalapati; Yi-Qiang Cheng; Herbert Chen; Renata Jaskula-Sztul Journal: Oncotarget Date: 2017-08-07